金城醫藥(300233.SZ):金城素智一車間口服混懸劑生產線通過GMP符合性檢查
格隆匯2月21日丨金城醫藥(300233.SZ)公佈,公司的全資子公司上海金城素智藥業有限公司(簡稱“金城素智”)收到上海市藥品監督管理局通知,金城素智“一車間口服混懸劑生產線(頭孢菌素類)(頭孢羥氨苄幹混懸劑)”符合《藥品生產質量管理規範》要求,通過上海市藥品監督管理局組織的藥品生產質量管理規範符合性檢查(以下簡稱“GMP 符合性檢查”)。
頭孢羥氨苄作為第一代頭孢菌素類抗菌藥物,是臨牀上常用的抗感染口服藥物。金城素智頭孢羥氨苄幹混懸劑 2.5g(250mg/5ml)、5g(500mg/5ml)於 2023年 6 月獲得《藥品註冊證書》,視同通過仿製藥質量和療效一致性評價。幹混懸劑兼顧固體制劑容易存儲攜帶、液體制劑容易吞嚥等優勢,可滿足兒童和老人等特殊人羣用藥需求。米內網數據顯示,頭孢羥氨苄相關製劑城市公立醫院 2020年至 2022 年全國銷售額約為 5,800 萬元人民幣、8,800 萬元人民幣、9,700 萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.